Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
Using bioinformatics and genomics to treat AML

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.06.19
Views: 493
Rating:

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany

Prof Torsten Haferlach speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the future of AML treatment.

He outlines how complex the many new treatments for AML are, and what we can do to identify which treatment is best for a specific patient.

Prof Haferlach speaks primarily from a genomic perspective, and how important it is to implement bioinformatic and artificial intelligence approaches to handle this data.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation